N
3.02
0.03 (1.00%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | NRX Pharmaceuticals, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
0.9
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 1.0 |
| 技术振荡指标 | 0.5 |
| 平均 | 0.88 |
|
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 23.56% |
| 机构持股比例 | 6.05% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| One Wealth Management Investment & Advisory Services, Llc | 31 Dec 2024 | 15,041 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 45.00 (Ascendiant Capital, 1,390.07%) | 购买 |
| 中 | 31.00 (926.49%) | |
| 低 | 19.00 (HC Wainwright & Co., 529.14%) | 购买 |
| 平均值 | 31.67 (948.68%) | |
| 总计 | 3 购买 | |
| 平均价格@调整类型 | 2.07 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| D. Boral Capital | 28 Jan 2025 | 31.00 (926.49%) | 购买 | 3.55 |
| 06 Jan 2025 | 31.00 (926.49%) | 购买 | 3.51 | |
| Ascendiant Capital | 02 Dec 2024 | 45.00 (1,390.07%) | 购买 | 1.35 |
| HC Wainwright & Co. | 25 Nov 2024 | 19.00 (529.14%) | 购买 | 1.31 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合